Healthy volunteers to test safety of combining liver fibrosis drug with hepatitis b antivirals
NCT ID NCT07295873
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 18 times
Summary
This early-stage study looks at how a new drug for liver scarring (hydronidone) interacts with four standard hepatitis B medications in 64 healthy adults. The goal is to measure drug levels in the blood and check for any harmful interactions. Results will help doctors prescribe these drugs together safely in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gaobo Hospital
Beijing, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.